Anemia
📧 Sign up to get email alerts when something new happens for Anemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG
The EMA authorises Silapo (epoetin zeta) by Stada Arzneimittel AG for treating anemia associated with cancer, chronic kidney failure, and bl…
-
EMA approval · 2026-07-20EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG
Authorised status for Retacrit (epoetin zeta) by EMA for use in anemia-related indications, including kidney failure, cancer-related anemia,…
-
EMA approval · 2026-07-03EMA Authorised: NeoRecormon (epoetin beta) — Roche Registration GmbH
NeoRecormon (epoetin beta) has been authorised by the EMA for related indications in chronic kidney failure, anemia, cancer, and autologous …
-
EMA approval · 2026-04-28EMA Authorised: Xromi (hydroxycarbamide) — Lipomed GmbH
Xromi (hydroxycarbamide) has been authorised in the EU for use in anemia and sickle cell disease.
-
EMA approval · 2026-04-28EMA Authorised: Siklos (hydroxycarbamide) — Theravia
Authorization of Siklos (hydroxycarbamide) in the European market for anemia and sickle cell indications.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-10EMA Authorised: Evrenzo (roxadustat) — Astellas Pharma Europe B.V.
EMA authorised Evrenzo (roxadustat) for the treatment of anemia associated with chronic kidney disease.
-
EMA approval · 2026-03-24EMA Authorised: Vafseo (vadadustat) — Medice Arzneimittel Pütter GmbH & Co. KG
The EMA authorised vadadustat (brand Vafseo) for the treatment of anemia associated with chronic kidney disease in the EU.
-
EMA approval · 2026-03-02EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG
EMA authorised Retacrit (epoetin zeta) as a biosimilar epoetin for the treatment of anemia in chronic kidney disease and cancer, among other…
-
EMA approval · 2026-01-13EMA Authorised: Aranesp (darbepoetin alfa) — Amgen Europe B.V.
EMA authorised Aranesp (darbepoetin alfa) for anemia associated with cancer and chronic kidney disease.
-
EMA approval · 2025-11-24EMA Authorised: Reblozyl (Luspatercept) — Bristol Myers Squibb Pharma EEIG
The European Medicines Agency authorised Reblozyl (luspatercept) by Bristol Myers Squibb Pharma EEIG for treating anemia associated with bet…
-
EMA approval · 2025-11-03EMA Authorised: Xromi (hydroxycarbamide) — Lipomed GmbH
The EMA authorised Xromi, a hydroxycarbamide medicine from Lipomed GmbH, for indications in anemia and sickle cell disease.
-
EMA approval · 2025-07-11EMA Authorised: Epoetin Alfa Hexal (epoetin alfa) — Hexal AG
The EMA authorised Epoetin Alfa Hexal (epoetin alfa) from Hexal AG to treat anemia associated with chronic kidney disease and related condit…
-
EMA approval · 2025-07-11EMA Authorised: Binocrit (epoetin alfa) — Sandoz GmbH
EMA authorised Binocrit (epoetin alfa) by Sandoz GmbH for the treatment of anemia associated with chronic kidney disease, myelodysplastic sy…
-
EMA approval · 2025-07-11EMA Authorised: Abseamed (epoetin alfa) — Medice Arzneimittel Pütter GmbH Co. KG
EMA has authorised Abseamed, an epoetin alfa product by Medice, for treatment of anemia associated with chronic kidney disease and certain h…
-
EMA approval · 2025-05-15EMA Authorised: Rytelo (imetelstat) — Geron Netherlands B.V.
EMA authorised Rytelo (imetelstat) for the treatment of anemia in patients with myelodysplastic syndromes. The product has orphan medicine d…
-
EMA approval · 2025-05-02EMA Authorised: NeoRecormon (epoetin beta) — Roche Registration GmbH
The EMA authorised NeoRecormon (epoetin beta) from Roche Registration GmbH for multiple indications, including chronic kidney disease–relate…
-
EMA approval · 2025-04-15EMA Authorised: Mircera (Methoxy polyethylene glycol-epoetin beta) — Roche Registration GmbH
Mircera (methoxy polyethylene glycol-epoetin beta) has been authorized by the EMA for the treatment of anemia, including in chronic kidney d…
-
EMA approval · 2023-09-27EMA Authorised: Eporatio (epoetin theta) — Ratiopharm GmbH
Authorised status for Eporatio (epoetin theta) by Ratiopharm GmbH for treatment areas including chronic kidney failure, anemia, and cancer.
-
EMA approval · 2023-09-27EMA Authorised: Biopoin (epoetin theta) — Teva GmbH
Biopoin (epoetin theta) has been authorised by the EMA for indications including chronic kidney failure, anemia, and cancer.
-
EMA approval · 2020-11-25EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG
Silapo (epoetin zeta) has been authorised by the EMA for indications related to anemia associated with chronic kidney disease, cancer, and u…
-
FDA approval · 2018-12-20FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for ARANESP (darbepoetin alfa) submitted by Amgen, Inc. The action typically involves labeling or in…
-
FDA approval · 2007-03-09FDA Approved: PROCRIT — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for PROCRIT (erythropoietin/epoetin alfa) from Janssen Products, LP.